Nuritas is a Biotech company based in San Francisco, CA. It has raised $112M in total funding. Latest round: Series C. Backed by Clay Capital, Bono, The Edge.
Nuritas funding overview
Nuritas is a Biotech company based in San Francisco, CA. Nuritas has raised $112M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in January 2024. The round record for Nuritas runs through 2024; nothing later has been disclosed. Investors on record include Clay Capital, Bono, The Edge, Marc Benioff, Ali Partovi, Enterprise Ireland and 9 others. 15 distinct backers are named across the disclosed rounds.
Nuritas at a glance
Total raised
$112M
Latest round
Series C
Latest round date
January 2024
Industry
Biotech
Headquarters
San Francisco, CA
Notable investors
Clay Capital, Bono, The Edge, Marc Benioff, Ali Partovi, Enterprise Ireland, Cultivian Sandbox Ventures, Cleveland Avenue
Frequently asked about Nuritas funding
How much has Nuritas raised?
Nuritas has raised $112M in total disclosed funding across the rounds on record.
Who has invested in Nuritas?
Clay Capital, Bono, The Edge, Marc Benioff, Ali Partovi, Enterprise Ireland are named among the investors backing Nuritas.
What was the latest Nuritas funding round?
The most recent disclosed round is a Series C, announced in January 2024.
Where is Nuritas based?
Nuritas is based in San Francisco, CA.
What sector does Nuritas operate in?
Nuritas is tracked under Biotech from San Francisco, CA, with $112M in disclosed funding.
When did Nuritas last raise?
The last disclosed Nuritas round closed in January 2024 at Series C.
Round data for Nuritas is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the Biotech companies in San Francisco and backer lists below.
